Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.
about
Ebola virus disease and critical illness.A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?Insights from clinical research completed during the west Africa Ebola virus disease epidemic.Transcriptomic analysis reveals a previously unknown role for CD8+ T-cells in rVSV-EBOV mediated protection.Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.Fighting Ebola: A Window for Vaccine Re-evaluation?Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia.Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection.T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection.A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.Ebola vaccines in clinical trial: The promising candidates.Ebola virus disease candidate vaccines under evaluation in clinical trials.Multivalent and Multipathogen Viral Vector Vaccines.Ebola virus vaccines - reality or fiction?Development of replication-deficient adenovirus malaria vaccines.Open-label phase I clinical trial of Ad5-EBOV in Africans in China.Personalized vaccinology: A review.Vaccines against 'the other' Ebolavirus species.A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products.Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine.Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.Accelerating Vaccine Development During the 2013-2016 West African Ebola Virus Disease Outbreak.Virus-Vectored Ebola Vaccines.From bench to almost bedside: the long road to a licensed Ebola virus vaccine.Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials.Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): Ebola virus diseaseA Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge.Willingness to Pay for an Ebola Vaccine during the 2014-2016 Ebola Outbreak in West Africa: Results from a U.S. National Sample.Development of novel vaccine vectors: Chimpanzee adenoviral vectors.Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic.Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteins.Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane.Immune barriers of Ebola virus infection.Lessons learned from Ebola Vaccine R&D during a public health emergency.Distinct Immunogenicity and Efficacy of Poxvirus-based Vaccine Candidates against Ebola Virus expressing GP and VP40 Proteins.The current landscape of nucleic acid tests for filovirus detection.Simian adenoviruses as vaccine vectors.Catching Chances: The Movement to Be on the Ground and Research Ready before an Outbreak
P2860
Q26250274-1FB65C5B-2D97-49F6-9936-4217BFEAE36BQ29994671-D409C7D4-A995-42C6-8933-DBC5A88C3309Q30234590-C832CE9D-0213-45BC-967F-73C4EE0767C8Q33681247-7F34F409-63DE-49A0-8B64-92F618C8D5D9Q33715773-633017BD-4C91-4135-BB92-C47BC3211F75Q33724960-D974042A-4823-45E9-BA16-EB3C59B671D9Q34540207-7868DF3D-9014-4DB0-B03C-79013B889E01Q36247762-364294D3-11E6-4E97-993E-C64202B457A0Q37713766-89B927DC-464E-47EA-BB79-904703228C9CQ37742680-9128B5AC-5502-43B3-A4E2-2FAF5723AB44Q38674025-0A5FD3FA-AFB6-48CA-BE5A-AA2BB902DDBAQ38730996-C508BB0F-3608-45CB-9E9D-E7A10B4C9399Q38808678-17FDA9A5-0834-4DC4-9FB2-136778A76B5AQ38830109-021E4C39-7164-4802-9BBE-0A2B0A838562Q38830323-1B52565C-00DC-455C-902A-B19E82D1AAD7Q38881265-2668E6EE-F0A2-49F1-8001-BB1E5A772C88Q38949194-54CB88C3-32E9-459E-AABC-398A16F9F563Q40048316-9D49A60F-5415-42E1-85EA-880A7BCAEF00Q40107665-82CAC2DD-C7A9-4881-BB33-C2C4B64313D1Q40112699-17354340-3D83-4BF6-B3AC-02046F8DB14FQ40548641-8085AFF9-22FA-4919-BD15-4F4A29CAAEE9Q41699782-92A1A91B-993E-4DAD-A348-82EF282F7A49Q41918936-B40B5F0E-4BC5-486F-B405-CC2D033C5353Q41936026-71A1FA7E-B303-40DC-BBAF-05C165F26053Q43284379-3A100C0E-55F7-448A-BAD9-4256E65545C9Q44106264-4A9772B8-77DE-4BA8-A72F-37898C77D97DQ47116619-CE9CF37F-B200-4F09-919F-97825D1E22B3Q47159908-3747B03D-8D8D-4218-A6F2-13CAE1E13748Q47552796-362FBE9F-1DE2-410B-AE78-DA2503024027Q47553674-83BB5D51-899D-45D5-911F-E4EAB148DD94Q47558190-FED577FA-9DB2-4697-8D80-2C1274F8B913Q47570091-8F6AEEE1-6ECB-4F57-860C-8F38BAD0DBC8Q47574658-6BCC3966-2FC4-4C27-BA40-9D3E71D34F9FQ47607706-942DAAE3-8A9A-43BB-AEF5-5E6623CCE945Q49917351-26A3D43D-5F11-4826-AFE7-6E988F561C54Q49923762-7545F5F7-37FE-4755-81AF-8E8EE38A19F5Q51784219-603F3A32-1800-4A61-B7A6-01F2CA71CFF2Q52602138-2FD28F02-8DDE-4C83-A1AD-4455FEFA4253Q54531277-9589B369-C502-4960-967F-3CD3CBE2DA5CQ56535643-375A421C-6D8E-4C34-B54E-3724850DF463
P2860
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Safety and immunogenicity of a ...... ose-finding, phase 1/2a study.
@ast
Safety and immunogenicity of a ...... ose-finding, phase 1/2a study.
@en
Safety and immunogenicity of a ...... ose-finding, phase 1/2a study.
@nl
type
label
Safety and immunogenicity of a ...... ose-finding, phase 1/2a study.
@ast
Safety and immunogenicity of a ...... ose-finding, phase 1/2a study.
@en
Safety and immunogenicity of a ...... ose-finding, phase 1/2a study.
@nl
prefLabel
Safety and immunogenicity of a ...... ose-finding, phase 1/2a study.
@ast
Safety and immunogenicity of a ...... ose-finding, phase 1/2a study.
@en
Safety and immunogenicity of a ...... ose-finding, phase 1/2a study.
@nl
P2093
P50
P921
P1476
Safety and immunogenicity of a ...... ose-finding, phase 1/2a study.
@en
P2093
Anne-Christine Thierry
Aurélie Ploquin
Camille Cochet
Carole Mayor
Daniel Estoppey
Emilie Pothin
François Roman
François Spertini
Laure Vallotton
Loane Warpelin-Decrausaz
P304
P356
10.1016/S1473-3099(15)00486-7
P50
P577
2015-12-22T00:00:00Z